Descárgate aquí la Guía Dislipemias 2016
![](https://sadeno.es/wp-content/uploads/2022/02/photo-1529119368496-2dfda6ec2804-768x768-2-landscape.jpg)
Publicaciones Similares
Guidelines Osteoporosis
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians Descarga aquí el artículo
Video resumen de la Jornada Lipid Expert Day
En el siguiente video podrá ver un completo resumen de la Jornada Lipid Expert Day, celebrada e pasado 6 de junio en el Palacio de Congresos y Exposiciones Ciudad de Oviedo. Durante la Jornada se analizaron temas de diversa índole como, Técnicas de imagen para valoración de la aterosclerosis; que corrió a cargo del Dr. Leopoldo Pérez…
Artículo Diamond Study Group
Está disponible para descarga el artículo Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Insulin Injections. Autores: RoyW. Beck, MD, PhD; Tonya Riddlesworth, PhD; Katrina Ruedy, MSPH; Andrew Ahmann, MD; Richard Bergenstal, MD; Stacie Haller, RD, LD, CDE; Craig Kollman, PhD; Davida Kruger, MSN, APN-BC; Janet B….
Evolocumab and Clinical Outcomes in Patients with Card. Disease
Descargue el artículo completo ABSTRACT BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels…
Evidencias de los nuevos tratamientos para el colesterol
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between progressively lower…
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial
Consulta aquí el artículo: Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial